Wissenschaftliche Projekte, Studien, Veröffentlichungen, Fortbildungs-Veranstaltungen und Ausbildung gehören neben unserer Kerntätigkeit zu den Aufgaben eines Lehrkrankenhauses.

Hier finden Sie weitere Informationen zu unseren Veröffentlichungen:

Ferdinandus J, Barbato F, Chodyla M, Fendler WP, Kessler L, Pomykala KL, Metzenmacher M, Krefting F, Hager T, Umutlu L, Herrmann K, Christoph DC (2020): Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma. J Nucl Med., in Druck.

Jia Z, Wang Y, Cao L, Wang Y, Song Y, Yang X, Bing Z, Cao Z, Liu P, Zhang S, Chen Z, Huang M, Yu Y, Han-Zhang H, Song J, Christoph DC, Passaro A, Gridelli C, Hishida T, Liang N, Li S (2020): First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up. J Thorac Dis. 12(7):3764-3773.

Staehler M, Stöckle M, Christoph DC, Stenzl A, Potthoff K, Grimm MO, Klein D, Harde J, Brüning F, Goebell PJ, Augustin M, Roos F, Benz-Rüd I, Marschner N, Grünwald V (2020): Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial. Int J Cancer, in Druck.

Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Schütt P, Steger F, Brückl WM, Christoph DC (2020): Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer 150:114-122.

Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Schütt P, Steger F, Brückl WM, Christoph DC (2020). Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP. Data Brief 34:106556.

Fehr M, Hawle H, Hayoz S, …… Stahl M, Ruhstaller T, for the Swiss Group for Clinical Cancer Research (SAKK) the German Esophageal Cancer Study Group, the Austrian Arbeitsgemeinschaft Medikamenöse Tumortherapie (AGMT) and the Federation de Cancerologie Digestive (FFCD) / Federation de Recherche en Chirurgie (FRENCH) (2020) High thrombembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08. BMC Cancer 20:166-174.

Lorenzen S, Knorrenschild J, Pauligk C, Hegewisch-Becker S, Seraphin J, Thuss-Patience P, Knopp H, Dechow T, Vogel A, Luley K, Pink D, Stahl M, Kullmann F, Hebart H, Siveke J, Egger M, Homann N, Probst S, Goetze T, Al-Batran S. (2020) Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Int J Cancer 147:2493-2502.Folprecht G, Trautmann K, Stein A, Huebner G, Stahl M, Kasper S, Kretzmar A, Köhne CH, ….. Krämer A, Arbeitsgemeinschaft Internistische Onkologie – CUP Group (2020) Adding Cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the phase II AIO trial PACET-CUP. Brit J Cancer, in Druck.

Girard N, Fietkau R, Garassino M, Garrido P, Field JK, Peters S, Smit HJM, Pérol M, Merle P, Sibille A, Markman B, Bouchaab H, Moskovitz M, Schumann C, Gregorc V, Klein AB, Diaz Perez I, Sawyer W, Licour M, Christoph D (2020): Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Ann Oncol. 31 (S4), P1242. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology 2020.

 

Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska -Lange A, Aries SP, Sackmann S, Schuett P, Steger F, Christoph D (2020): Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP) Ann Oncol. 31 (S4), P1244.

Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology 2020.

 

Christoph DC, Barbato F, Chodyla M-K, Fendler WP, Kessler L, Pomykala KL, Metzenmacher M, Krefting F, Hager T, Herrmann K, Ferdinandus J (2020): Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma. Ann Oncol. 31 (S4), MO1896. Kurzvortrag auf der Jahrestagung der European Society of Medical Oncology 2020.

 

Christoph DC, Rizzo F, Kambartel K-O, Winke S, Panse J, Abdulla DS, Scheffler M, Azeh IT, Hoiczyk M, Turki A, Metzenmacher M (202):  Docetaxel/nindetanib as efficient treatment option after failure of immune checkpoint inhibition: Real-world evidence. Ann Oncol. 31 (S4), P1374. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology 2020.

 

Shah R, Klotz LV, Feißt M, Schneider M, Kriegsmann M, Ried M, Wesseler C, Christoph DC, de Wit M, Jürgens J, Kopp H-G, Wehler T, Reck M, Sackmann S, Waller C, Reinmuth N,  Bischoff H, Winter H , Eichhorn M, Thomas M (2020):  NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery. Ann Oncol. 31 (S4), TiP1912. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology 2020.

Eine Auflistung unserer aktuell durchgeführten Studien finden Sie hier:

Studiennummer: DESTINY-Gastric04 (DS8201-A-U306)
Studientitel: Eine multizentrische, zweiarmige, randomisierte, offene Phase III Studie zu Trastuzumab-Deruxtecan bei Teilnehmern mit HER2-positivem metastasiertem und/oder inoperablem Adenokarzinom des Magens oder des gastroösophagealen Übergangs (GEJ), bei denen es während oder nach einem Trastuzumab-haltigen Regime zu einer Progression gekommen ist
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: VESTIGE (1707-GITCG)
Studientitel: Adjuvante Immuntherapie bei Patienten mit reseziertem Magenkarzinom im Anschluss an eine präoperative Chemotherapie mit hohem Rezidivrisiko (N+ und/oder R1) – eine offene, randomisierte, kontrollierte Phase-II-Studie
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: Skycraper-07 (YO42137)
Studientitel: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: Renaissance (ReCure-FLOT 5-RAVE)
Studientitel: Chemotherapy alone vs. Chemotherapy followed by surgical resection for limited metastatic adenocarcinoma of the stomach or esphagogastric junction-a randomized multicenter phase III trial of the AIO in cooperation with CAO-V/CAOGI
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: Ramiris II/III
Studientitel: Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: RACE
Studientitel: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ)
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: Fire-9-Port (AIO-KRK-0418):  
Studientitel: Post-resection/ablation chemotherapy in patients with metastatic colorectal cancer
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: RAMTAS (AIO-KRK-0316)
Studientitel: Adjuvante Immuntherapie bei Patienten mit reseziertem Magenkarzinom im Anschluss an eine präoperative Chemotherapie mit hohem Rezidivrisiko (N+ und/oder R1) – eine offene, randomisierte, kontrollierte Phase-II-Studie
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: ACO/ARO/AIO 18.1
Studientitel: Short-course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patients.
A randomized phase III trial of the German Rectal Cancer Study Group
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet

Studiennummer: ACO/ARO/AIO 18.2
Studientitel: Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure:
A randomized phase III trial of the German Rectal Cancer Study Group
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: Elderly (AIO-KRK-0117)
Studientitel: Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for elderly or frail elderly patients with metastatic colorectal cancer
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: Cirulate (AIO-KRK-0217)
Studientitel: Circulating tumor DNA based decision for adjuvant treatment in colon cancer stage II evaluation.
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet

Studiennummer: CheckMate (CA209-274)
Studientitel: A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 274)
Verantwortlicher Arzt: Prof. Dr. Susanne Krege
Status: geöffnet

Studiennummer: FOOTPATH
Studientitel: A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet

Studiennummer: IMforte (GO43104)
Studientitel: A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF LURBINECTEDIN IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH ATEZOLIZUMAB AS MAINTENANCE THERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC) FOLLOWING FIRST-LINE INDUCTION THERAPY WITH CARBOPLATIN, ETOPOSIDE AND ATEZOLIZUMAB
Verantwortlicher Arzt: Dr. Daniel Christoph
Status: geöffnet

Studiennummer: CA2244-104
Studientitel: A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Verantwortlicher Arzt: Dr. Daniel Christoph
Status: geöffnet

Studiennummer:  Mirati-849-012 (Krystal)
Studientitel: A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Verantwortlicher Arzt: Dr. Daniel Christoph
Status: geöffnet

Studiennummer: Dolpin
Studientitel: A Phase II randomized Study to evaluate the efficacy and safety of Cisplatin / Etoposide and concomitant radiotherapy combined with Durvalumab followed by Maintenance Therapy with Durvalumab versus Cisplatin / Etoposide and concomitant Radiotherapy in Patients with limited disease Small Cell Lung Cancer
Verantwortlicher Arzt: Dr. Daniel Christoph
Status: geöffnet

Studiennummer: NICITA
Studientitel: Nivolumab with chemotherapy in pleural mesothelioma after surgery
Verantwortlicher Arzt: Dr. Daniel Christoph
Status: geöffnet

Studiennummer: CheckMate 73L (CA209-73L)
Studientitel: A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer
(CheckMate 73L: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 73L)
Verantwortlicher Arzt: Dr. Daniel Christoph
Status: geöffnet

Studiennummer: Cupisco (MX39795)
Studientitel: A PHASE II, RANDOMIZED, ACTIVE-CONTROLLED, MULTI-CENTER STUDY COMPARING THE EFFICACY AND SAFETY OF TARGETED THERAPY OR CANCER IMMUNOTHERAPY GUIDED BY GENOMIC PROFILING VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY SITE WHO HAVE RECEIVED THREE CYCLES OF PLATINUM DOUBLET CHEMOTHERAPY
Verantwortlicher Arzt: Prof. Dr. Michael Stahl
Status: geöffnet